{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:19:02Z","timestamp":1781925542041,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02842-9","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T06:02:01Z","timestamp":1713592921000},"page":"3017-3027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023\u2014A Podcast"],"prefix":"10.1007","volume":"41","author":[{"given":"Luciano J.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"issue":"suppl 1","key":"2842_CR1","doi-asserted-by":"publisher","first-page":"6727","DOI":"10.1182\/blood-2023-180984","volume":"142","author":"C Charalampous","year":"2023","unstructured":"Charalampous C, Kumar SK, Parrondo R, et al. Patient-reported outcomes among patients with triple-class refractory multiple myeloma in real-world clinical practice: a prospective, multi-site observational study. Blood. 2023;142(suppl 1):6727.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2023-179152","volume":"142","author":"M Delforge","year":"2023","unstructured":"Delforge M, Patel KK, Eliason L, et al. Effects of idecabtagene bicleucel (Ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed\/refractory multiple myeloma (RRMM) who had received 2\u20134 prior regimens: updated results from the phase\u00a03 KarMMa-3 trial. Blood. 2023;142(suppl 1):96.","journal-title":"Blood"},{"issue":"1","key":"2842_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase\u00a03, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2842_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","volume":"24","author":"TG Martin","year":"2023","unstructured":"Martin TG, Moreau P, Usmani SZ, et al. Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase\u00a0II MajesTEC-1 study. Clin Lymphoma Myeloma Leuk. 2023;24(3):194\u2013202.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2842_CR5","doi-asserted-by":"crossref","unstructured":"Mohty M, Bahlis N, Nooka AK, et al. The effect of elranatamab on patient-reported outcomes in patients with relapsed\/refractory multiple myeloma naive and exposed to B-cell maturation antigen (BCMA)-directed therapies: results from the MagnetisMM-3 study. In: Poster presented at the 20th International Myeloma Society Meeting. September 27\u201330, 2023; Athens, Greece.","DOI":"10.1016\/S2152-2650(23)02091-8"},{"issue":"suppl 1","key":"2842_CR6","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1182\/blood-2023-178824","volume":"142","author":"K Radwanski","year":"2023","unstructured":"Radwanski K, Yu J, Pierce K, et al. Real-world evaluation of outcomes in relapsed\/refractory multiple myeloma patients that are triple-class exposed after receiving 2 or more prior lines of therapy. Blood. 2023;142(suppl 1):3358.","journal-title":"Blood"},{"key":"2842_CR7","unstructured":"Carvykti (ciltacabtagene autoleucel) [package insert]. Horsham, PA: Janssen; 2023."},{"key":"2842_CR8","unstructured":"Carvykti (ciltacabtagene autoleucel) [summary of product characteristics]. Leiden, Netherlands: Janssen; 2023."},{"key":"2842_CR9","unstructured":"Abecma (idecabtagene vicleucel) [summary of product characteristics]. Dublin, Ireland: Bristol-Myers Squibb; 2022."},{"key":"2842_CR10","unstructured":"Abecma (ideccabtagene vicleucel) [package insert]. Summit, NJ: Celgene; 2024."},{"issue":"suppl 1","key":"2842_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2023-180421","volume":"142","author":"D Dima","year":"2023","unstructured":"Dima D, Davis JA, Ahmed N, et al. Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma. Blood. 2023;142(suppl 1):91.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1182\/blood-2023-174875","volume":"142","author":"M Mohan","year":"2023","unstructured":"Mohan M, Shah N, Luan D, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood. 2023;142(suppl 1):545.","journal-title":"Blood"},{"issue":"6","key":"2842_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"11","key":"2842_CR14","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1002\/ajh.27063","volume":"98","author":"L Joiner","year":"2023","unstructured":"Joiner L, Bal S, Godby KN, Costa LJ. Teclistamab in patients with multiple myeloma and impaired renal function. Am J Hematol. 2023;98(11):e322\u20134.","journal-title":"Am J Hematol"},{"key":"2842_CR15","unstructured":"Elrexfio (elranatamab-bcmm) [package insert]. New York, NY: Pfizer; 2023."},{"key":"2842_CR16","unstructured":"Tecvayli (teclistamab-cqyv) [package insert]. Horsham, PA: Janssen; 2023."},{"key":"2842_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s40495-017-0090-5","volume":"3","author":"Y Chen","year":"2017","unstructured":"Chen Y, Xu Y. Pharmacokinetics of bispecific antibody. Curr Pharmacol Rep. 2017;3:126\u201337.","journal-title":"Curr Pharmacol Rep"},{"issue":"suppl 1","key":"2842_CR18","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1182\/blood-2023-180660","volume":"142","author":"F Lachenal","year":"2023","unstructured":"Lachenal F, Lebreton P, Bouillie S, et al. Teclistamab in relapsed refractory multiple myeloma patients on dialysis: a French experience. Blood. 2023;142(suppl 1):4739\u20134739.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2023-189229","volume":"142","author":"H Mian","year":"2023","unstructured":"Mian H, Harper JS, Le HH, et al. Real-world treatment patterns and clinical outcomes among triple-class exposed and B-cell maturation antigen (BCMA) exposed multiple myeloma patients. Blood. 2023;142(suppl 1):542.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR20","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood-2023-186269","volume":"142","author":"SC Quinn","year":"2023","unstructured":"Quinn SC, Kelly L, Lewis T. The additional disease burden accompanying a delayed diagnosis of multiple myeloma: utilising a large real-world evidence base. Blood. 2023;142(suppl 1):3771.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2023-188272","volume":"142","author":"G Ravi","year":"2023","unstructured":"Ravi G, Bal S, Godby K, et al. Outcomes of patients with newly diagnosed multiple myeloma experiencing treatment failure after upfront quadruplet therapy and autologous stem cell transplantation. Blood. 2023;142(suppl 1):1989.","journal-title":"Blood"},{"issue":"suppl 1","key":"2842_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase\u00a0III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142(suppl 1):4.","journal-title":"Blood"},{"issue":"4","key":"2842_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02842-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:10:59Z","timestamp":1721675459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02842-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02842-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luciano J. Costa has received honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, and Sanofi; has acted as consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm Therapeutics; has received research funding from Amgen, Bristol Myers Squibb, Celgene, Janssen, and Juno; and has participated in Speakers\u2019 Bureaus for Amgen and Sanofi. Paula Rodriguez-Otero has received honoraria from AbbVie, Celgene, GSK, H3 Biomedicine, Janssen, Pfizer, and Sanofi; has acted as a consultant for AbbVie, Bristol Myers Squibb, GSK, Janssen, Pfizer, and Sanofi; has participated in Speaker\u2019s Bureaus for Bristol Myers Squibb, GSK, Janssen, and Sanofi; and has received funds for travel expenses from Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}